PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.

Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferation and induce apoptosis of JAK2V617F-mutant cell lines.

Patients And Methods: In a phase I dose-escalation and -expansion study, we evaluated the safety and efficacy of a selective PI3Kδ inhibitor, umbralisib, in combination with ruxolitinib in patients with MF who had a suboptimal response or lost response to ruxolitinib.

Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.

Objective: To discuss the mechanism of action and nursing care of adults receiving chimeric antigen receptor (CAR) T-cell therapy.

Data Source: Peer reviewed articles and pharmaceutical drug labels.

Conclusion: CAR T-cell therapy is among the most exciting therapies in the evolution of cancer treatment.

Management Principles Associated With Cytokine Release Syndrome.

Objective: To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS).

Data Sources: A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events.

Conclusion: Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research.

Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients.

Hematopoietic stem cell transplantation (HCT) survivors are less likely than matched healthy controls to mount a strong immune response to trivalent inactivated influenza vaccine (TIV). High-dose (HD) or standard-dose (SD) TIV were given to adult HCT subjects 18 years or older at least 6 months after transplantation. Subjects were randomized 2:1 to receive either the HD (60 μg hemagglutinin [HA]/strain/dose) or the SD (15 μg HA/strain/dose) TIV.